Features and properties of regdanvimab

Alternative names	CT-P59; Regkirona
Class	Antivirals; Monoclonal antibodies
Mechanism of action	Virus internalisation inhibitors
Route of administration	Intravenous infusion
Pharmacodynamics	Neutralizes severe acute respiratory syndrome coronavirus 2 by binding to the receptor binding domain of the virus’ spike protein; decreases viral load in upper and lower respiratory tracts in animal models
Pharmacokinetics	Dose-proportional pharmacokinetics over a dose range of 20–80 mg/kg; median time to maximum plasma concentration 2.5 h; low clearance (0.227 mL/kg for 40 mg/kg); small volume of distribution (87.2 mL/kg for 40 mg/kg); terminal half-life 12 days; eliminated through normal immunoglobulin degradation pathways
Most frequent adverse events	Hypertriglyceridemia
ATC codes
WHO ATC code	J05A-X (Other antivirals)
EphMRA ATC code	J5B (Antivirals, excluding anti-HIV products)
CAS Registry Number	2444308-95-4